In a clinical study, at 26 weeks, more than half of the patients on HUMIRA saw significant symptom relief and many achieved remission. HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and maintain clinical remission in children 6 years of age and older with moderate to severe Crohn’s disease when certain other treatments have not worked well enough.
HUMIRA was first approved in the United States in 2002 as a biologic therapy. It has been studied in 76 different clinical trials worldwide, and it’s approved in the US for 8 different conditions, including moderate to severe Crohn’s disease in adults in 2007, moderate to severe juvenile idiopathic arthritis in children 2 years of age and older in 2008, and moderate to severe pediatric Crohn's disease in children 6 years of age and older in 2014. Over one million patients are currently being treated with HUMIRA worldwide.*3
HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and maintain clinical remission in adults with moderate to severe Crohn’s disease who have not responded well to conventional treatments. HUMIRA is also used to reduce signs and symptoms and achieve clinical remission in these adults who have also lost response to or are unable to tolerate infliximab.
HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children 4 years of age and older.
*As of June 2016.
Some people receiving TNF blockers including HUMIRA developed a rare type of cancer called hepatosplenic T-cell lymphoma (HSTCL), which often results in death. Most of these people were male teenagers or young men and also were being treated for inflammatory bowel disease with another medicine called Imuran®† (azathioprine) or Purinethol®† (6-mercaptopurine, 6–MP).
†All trademarks are the property of their respective companies.
HUMIRA is not right for everyone.
You may choose to have a HUMIRA Ambassador who is provided at no additional cost and offers one-to-one personalized support. Your Ambassador has received in-depth training on pediatric Crohn's disease and HUMIRA.
HUMIRA Ambassador services are available through HUMIRA Complete, an optional product support program offered to you by AbbVie that includes services such as injection training from a local registered nurse, financial assistance information, a HUMIRA Complete Co-pay Savings Card‡ (if eligible), and more. Your HUMIRA Ambassador can provide you and your child with one-to-one customized education and support as well as assist you with the other resources provided through HUMIRA Complete.
Call 1.800.4HUMIRA to connect with a HUMIRA Ambassador today (select the option to speak with a nurse).
‡Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: In Massachusetts, co-pay assistance is not available for products with certain generic equivalents (for example, any product with an AB-rated generic equivalent). Available to patients with commercial prescription insurance coverage for HUMIRA. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (for example, Medicare, Medicaid, TRICARE, Department of Defense or Veteran's Affairs programs) or where prohibited by law. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
Tell your doctor about all of your health conditions, including if you:
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
HUMIRA can cause serious side effects, including:
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
HUMIRA is given by injection under the skin.
HUMIRA is a prescription medicine used:
HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and maintain clinical remission in children 6 years of age and older with moderate to severe Crohn’s disease when certain other treatments have not worked well enough.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. HUMIRA may increase the chance of getting lymphoma, including a rare kind, or other cancers. HUMIRA can cause serious side effects including hepatitis B infection in carriers of the virus, allergic reactions, nervous system problems, blood problems, heart failure, certain immune reactions including a lupus-like syndrome, liver problems, and new or worsening psoriasis.